Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

XU Xiaoxia, MIN Tao, SHI Weilong. Improved synthesis of imatinib mesylate[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 290-293. doi: 10.3969/j.issn.1006-0111.2014.04.014
Citation: XU Xiaoxia, MIN Tao, SHI Weilong. Improved synthesis of imatinib mesylate[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 290-293. doi: 10.3969/j.issn.1006-0111.2014.04.014

Improved synthesis of imatinib mesylate

doi: 10.3969/j.issn.1006-0111.2014.04.014
  • Received Date: 2013-03-12
  • Rev Recd Date: 2013-12-05
  • Objective To obtain the improved synthesis of imatinib mesylate. Methods 4-[(4-methyl-piperazin-1-yl) methyl] benzoyl chloride dihydrochloride and 4-methyl-N3-[4-(3-pyridyl) pyrimidin-2-yl]-1,3-phenylenediamine were used as starting raw material to perform a condensation reaction in the aqueous phase to give imatinib free base, which was then neutralized with methanesulfonic acid to obtain the novel antineoplastic tyrosinase inhibitor imatinib mesylate by the use of a two-step reaction. Results The improved synthesis was considered to have the advantages of low cost, easy post-processing, high purity, high yield and environmental pollution with the HPLC purity≥99.7% and the single impurity<0.1%. Conclusion The total yield of the novel method was 81.5%, having an enough broad industrial production prospect.The targeted compound structure was confirmed by 1H NMR and ESI-MS.
  • [1] 陈 敖,黄荷香,宋帅娟. 甲磺酸伊马替尼的合成[J]. 精细与专用化学品,2007,15(8):23-25.
    [2] 赵 瑾,姜 达. 甲磺酸伊马替尼耐药机制及其逆转研究进展[J]. 癌症进展杂志,2009,7(2):158-165.
    [3] 陈灵娟,周和平,黄文峰,等. 甲磺酸伊马替尼的合成[J]. 河北科技大学学报,2011,32(5):492-495.
    [4] 王保国,刘玉凤,狄国杰. 甲磺酸伊马替尼的合成[J]. 济宁医学院学报,2012,35(2):103-105.
    [5] 齐默尔曼 J. 嘧啶衍生物及其制备方法[P]. 中国专利,93103566,1993-10-27.
    [6] Kompella A,Bhujanga RA,Venkaiah CN,et al. Process for the preparation of the anti-cancer drug imatinib and its analogues[P]. 世界专利,2004108699,2004-12-16.
    [7] 卢瓦瑟勒尔, 考夫曼, 阿贝尔,等. N-苯基-2-嘧啶胺衍生物[P]. 中国专利,03803556,2003-02-06.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(3124) PDF downloads(325) Cited by()

Related
Proportional views

Improved synthesis of imatinib mesylate

doi: 10.3969/j.issn.1006-0111.2014.04.014

Abstract: Objective To obtain the improved synthesis of imatinib mesylate. Methods 4-[(4-methyl-piperazin-1-yl) methyl] benzoyl chloride dihydrochloride and 4-methyl-N3-[4-(3-pyridyl) pyrimidin-2-yl]-1,3-phenylenediamine were used as starting raw material to perform a condensation reaction in the aqueous phase to give imatinib free base, which was then neutralized with methanesulfonic acid to obtain the novel antineoplastic tyrosinase inhibitor imatinib mesylate by the use of a two-step reaction. Results The improved synthesis was considered to have the advantages of low cost, easy post-processing, high purity, high yield and environmental pollution with the HPLC purity≥99.7% and the single impurity<0.1%. Conclusion The total yield of the novel method was 81.5%, having an enough broad industrial production prospect.The targeted compound structure was confirmed by 1H NMR and ESI-MS.

XU Xiaoxia, MIN Tao, SHI Weilong. Improved synthesis of imatinib mesylate[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 290-293. doi: 10.3969/j.issn.1006-0111.2014.04.014
Citation: XU Xiaoxia, MIN Tao, SHI Weilong. Improved synthesis of imatinib mesylate[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 290-293. doi: 10.3969/j.issn.1006-0111.2014.04.014
Reference (7)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return